IvonescimabClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Sponsor:

Summit Therapeutics

Code:

NCT05899608

Conditions

Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ivonescimab Injection

Pembrolizumab Injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Summit Therapeutics on 2026-04-30.